|Articles|February 21, 2017

Dose Form Development

Author(s)Catalent

Catalent is the leading global provider of advanced drug delivery technologies and development solutions, providing worldwide clinical and commercial supply capabilities for drugs, biologics, and consumer health products. The company has over 80 years’ experience serving the industry, and proven expertise in bringing more customer products to market faster, enhancing product performance, and ensuring reliable product supply.

 

 

Catalent’s solutions include analytical, pre-formulation and formulation, the recent addition of spray dry dispersion specialist Pharmatek, and biologics technologies and manufacture. Catalent now offers the most comprehensive toolkit of bioavailability enhancing technologies and the development of patient centric dose forms.

 

 

Catalent serves thousands of innovators, both established and emerging, in over 80 markets, including 48 of the top 50 pharmaceutical and 41 of the top 50 biotech companies. Its team of over 1,400 talented scientists has supported over half of all new molecular entities approved by the FDA in the past 10 years, and from more than 30 global sites it supplies more than 70 billion units annually, to customers in over 80 countries.

 

 

Whether an innovator is looking for a single, tailored solution, or multiple answers throughout a product’s lifecycle, Catalent can improve the total value of treatments, from discovery to market and beyond.

 

 

Catalent. More products. Better treatments. Reliably supplied.™

Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.